Elanco
ELAN
$24.50
+0.33%
Elanco Animal Health is a global animal health company that develops, manufactures, and markets pharmaceutical products for companion and food animals, operating in the Drug Manufacturers - Specialty & Generic industry. Spun off from Eli Lilly in 2018, Elanco has grown through strategic acquisitions, including Bayer Animal Health in 2020, establishing itself as a major player in the animal health sector. The current investor narrative centers on the company's turnaround execution, highlighted by strong Q1 2026 earnings, product momentum, and raised guidance, which have driven the stock's 40% gain over the past year. Investors are debating the sustainability of this growth and margin expansion as the company continues to deleverage and innovate.…
ELAN
Elanco
$24.50
Related headlines
Investment Opinion: Should I buy ELAN Today?
Based on the strong Q1 2026 performance, raised guidance, and analyst consensus of Strong Buy with an average target of $31.21, I rate ELAN a Buy. The company is executing well on its turnaround, and the stock offers a 27.4% upside to the average analyst target, with a low target of $26.00 still providing 6.1% upside. The thesis is supported by accelerating revenue growth of 14.92% YoY, a return to profitability with EPS of $0.11, and a gross margin expansion to 57.26% from 39.34% in the prior quarter.
Sign up to view all
ELAN 12-Month Price Forecast
The AI model assesses ELAN as bullish, driven by strong fundamental improvements and favorable valuation metrics. The company's ability to grow revenue while expanding margins suggests effective execution of its turnaround strategy. However, the high beta and debt levels introduce uncertainty, and the model's confidence is medium due to the volatility in recent earnings. If Elanco continues to deliver on its guidance and maintains margin expansion, the stock is likely to re-rate higher. Conversely, any signs of stagnation could lead to a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elanco's 12-month outlook, with a consensus price target around $31.21 and implied upside of +27.4% versus the current price.
Average Target
$31.21
0 analysts
Implied Upside
+27.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$26 - $34
Analyst target range
Analyst consensus is Strong Buy with a mean recommendation of 1.47 (1=Strong Buy, 5=Sell). 14 analysts cover the stock, with an average target price of $31.21, implying 27.4% upside from the current price of $24.50. The target range is $26.00 (low) to $34.00 (high), with the high target suggesting 38.8% upside, reflecting optimism about continued growth and margin expansion. Recent ratings actions have been positive, including upgrades from Piper Sandler (Neutral to Overweight) and reaffirmations from TD Cowen, Citigroup, and JP Morgan, indicating improving sentiment.
Bulls vs Bears: ELAN Investment Factors
Elanco presents a compelling turnaround story with strong Q1 2026 results, margin expansion, and raised guidance, which have driven a 40% stock rally. However, the company's high debt, volatile earnings history, and premium valuation introduce significant risks. The bull case currently has stronger evidence, supported by improving fundamentals and analyst optimism, but the key tension lies in whether the company can sustain its growth and margin improvements to justify its valuation. If Elanco continues to execute and deleverage, the stock could re-rate higher; if growth stalls or debt costs rise, the premium multiple could compress sharply.
Bullish
- Strong Q1 2026 earnings beat: Q1 2026 revenue grew 14.92% YoY to $1.371B, with EPS of $0.11, a sharp turnaround from the -$0.56 loss in Q4 2025. This demonstrates the company's ability to execute on its turnaround plan and has driven the stock up 40% over the past year.
- Significant gross margin expansion: Gross margin improved to 57.26% in Q1 2026 from 39.34% in Q4 2025, reflecting better product mix and cost controls. This 18 percentage point jump indicates strong operational leverage and potential for further profitability gains.
- Raised guidance and product momentum: Management raised full-year guidance following Q1 results, citing strong product momentum. This positive outlook is supported by recent analyst upgrades from Piper Sandler and reaffirmations from TD Cowen, Citigroup, and JP Morgan.
- Attractive forward valuation: With a forward PE of 19.15 and a PEG ratio of 0.28, the stock appears undervalued relative to its expected growth. The low PEG suggests the market is not fully pricing in the company's earnings acceleration potential.
Bearish
- High debt burden from acquisitions: Elanco carries significant debt from the Bayer acquisition, with a debt-to-equity ratio of 0.61 and interest expenses of $57M in Q1 2026 alone. This leverage increases financial risk and limits flexibility, especially if interest rates remain elevated.
- Inconsistent earnings history: The company has posted net losses in several recent quarters, including -$276M in Q4 2025 and -$34M in Q3 2025. This volatility makes it difficult to rely on sustained profitability, and the trailing PE is negative at -48.15.
- High volatility and beta: With a beta of 1.694, ELAN is 69% more volatile than the market. This amplifies downside risk during market selloffs, as evidenced by the 1-month price decline of -6.56% despite a positive 1-year trend.
- Potential overextension after rally: The stock is trading at 78% of its 52-week range, near the highs. The recent pullback from $27.98 to $24.50 suggests profit-taking, and the 1-month relative strength of -6.61% indicates short-term weakness.
ELAN Technical Analysis
Elanco's stock is in a clear uptrend over the past year, with a 1-year price change of +40.24%, significantly outperforming the S&P 500's +18.65% gain. The current price of $24.50 sits at 78% of its 52-week range (low $17.51, high $27.98), indicating the stock is trading closer to its highs, reflecting strong momentum but also potential overextension. The stock's beta of 1.694 suggests it is 69% more volatile than the market, which is important for risk assessment.
Beta
1.68
1.68x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$18-$28
Price range past year
Annual Return
+40.2%
Cumulative gain past year
| Period | ELAN Return | S&P 500 |
|---|---|---|
| 1m | -6.6% | -0.4% |
| 3m | +3.7% | +4.5% |
| 6m | +4.9% | +13.9% |
| 1y | +40.2% | +19.0% |
| ytd | +8.8% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELAN Fundamental Analysis
Elanco's revenue trajectory is improving, with Q1 2026 revenue of $1.371 billion, up 14.92% year-over-year, accelerating from the prior year's quarterly revenues (e.g., Q1 2025: $1.193B, Q2 2025: $1.241B). The company returned to profitability in Q1 2026 with net income of $57 million and EPS of $0.11, a significant turnaround from the net loss of -$276 million in Q4 2025. Gross margin expanded to 57.26% in Q1 2026, up from 39.34% in Q4 2025, reflecting improved product mix and cost controls.
Quarterly Revenue
$1.4B
2026-03
Revenue YoY Growth
+14.9%
YoY Comparison
Gross Margin
57.3%
Latest Quarter
Free Cash Flow
$315000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELAN Overvalued?
Given the positive net income in the most recent quarter, the PE ratio is the primary valuation metric. The trailing PE is -48.15 (due to negative TTM earnings), but the forward PE is 19.15, indicating the market expects strong earnings growth. The PEG ratio of 0.28 suggests the stock is undervalued relative to its growth rate, but this is based on forward estimates. Compared to the industry average, Elanco's forward PE of 19.15 is at a premium to the sector's average of 15x, reflecting its higher growth potential. Historically, the stock's forward PE is near the lower end of its 5-year range, suggesting it is not overvalued relative to its own history.
PE
-48.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~65x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are elevated due to Elanco's substantial debt load, with a debt-to-equity ratio of 0.61 and quarterly interest expenses around $57M. The company's earnings have been erratic, swinging from a -$276M loss in Q4 2025 to a $57M profit in Q1 2026, indicating vulnerability to operational hiccups. While free cash flow is positive at $315M TTM, it remains modest relative to debt obligations, and the negative trailing PE of -48.15 highlights the lack of consistent profitability. Margin expansion is encouraging, but the 57.26% gross margin in Q1 2026 may not be sustainable if input costs rise or product mix shifts unfavorably.
FAQ
The key risks include high debt levels (debt-to-equity of 0.61), which could strain cash flow if interest rates rise. Earnings volatility is another concern, as the company has posted losses in several recent quarters. Competitive pressures from larger players like Zoetis could erode market share, and the stock's high beta of 1.694 means it is susceptible to market downturns. Regulatory changes in animal health and potential product recalls are additional risks. Investors should monitor these factors closely.
The 12-month forecast for ELAN is positive, with a base case target of $28-31, reflecting the average analyst target of $31.21. The bull case, with a 30% probability, sees the stock reaching $34.00, while the bear case, with a 20% probability, could see it fall to $20-26. The most likely scenario is the base case, which assumes continued revenue growth of 12-14% and stable margins. Overall, the stock has a 27.4% upside to the average analyst target, making it an attractive investment.
ELAN is fairly valued relative to its growth prospects, with a forward PE of 19.15, which is a premium to the industry average of 15x. However, the PEG ratio of 0.28 indicates that the market is not fully pricing in the expected earnings growth, suggesting potential undervaluation. Historically, the stock's forward PE is near the lower end of its 5-year range, implying it is not overvalued. The market is pricing in a successful turnaround, and if Elanco delivers on its guidance, the stock could re-rate higher.
ELAN is a good buy for investors with a higher risk tolerance, given its strong Q1 2026 performance and analyst upside of 27.4% to the average target of $31.21. The stock's forward PE of 19.15 and PEG of 0.28 suggest it is undervalued relative to its growth potential. However, the high beta of 1.694 and debt levels mean it is not suitable for conservative investors. If you believe in the company's turnaround and can withstand volatility, ELAN offers a compelling risk-reward opportunity.
ELAN is more suitable for long-term investment, given its turnaround story and growth potential. The company is in the early stages of margin expansion and debt reduction, which could take several years to fully play out. The stock's high beta of 1.694 makes it volatile in the short term, as seen in the recent 1-month decline of -6.56%. For long-term investors with a 2-3 year horizon, the stock offers significant upside if the company executes its strategy. Short-term traders may find opportunities, but they should be prepared for sharp swings.